EMA Approves EU-Wide Rx-to-OTC Switch Of Fortacin
Executive Summary
Premature ejaculation treatment Fortacin is set to become only the fifth drug to achieve an Rx-to-OTC switch through EMA's centralized procedure, expanding the burgeoning OTC men's sexual health category.
You may also be interested in...
Fortacin Wins Commission Approval As Fifth EU-Wide Rx-To-OTC Switch
European Commission approval of Fortacin as OTC premature ejaculation treatment makes it only the fifth drug switched EU-wide through the centralized procedure.
EU-Wide Switch Of Premature Ejaculation Drug A Real Prospect
EMA's CHMP is considering an EU-wide switch of premature ejaculation drug Fortacin, with applicant Recordati eyeing a January 2021 launch for the OTC treatment.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: